Natco Pharma Usa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NATCO PHARMA USA
NATCO PHARMA USA has nineteen approved drugs.
Summary for Natco Pharma Usa
| US Patents: | 0 |
| Tradenames: | 15 |
| Ingredients: | 15 |
| NDAs: | 19 |
| Patent Litigation for Natco Pharma Usa: | See patent lawsuits for Natco Pharma Usa |
Drugs and US Patents for Natco Pharma Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natco Pharma Usa | DESMOPRESSIN ACETATE | desmopressin acetate | TABLET;ORAL | 200653-002 | Jun 27, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Natco Pharma Usa | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 078827-003 | Oct 26, 2016 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Natco Pharma Usa | RISPERIDONE | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 091537-006 | Feb 12, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Natco Pharma Usa | RISPERIDONE | risperidone | TABLET;ORAL | 076288-001 | Sep 15, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Natco Pharma Usa | RISPERIDONE | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 091537-005 | Mar 30, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Natco Pharma Usa | CARBOPLATIN | carboplatin | INJECTABLE;INJECTION | 091510-002 | May 29, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
